论文部分内容阅读
目的:观察黄荆子乙酸乙酯提取物(EVn-50)对人肝癌Hep G2裸鼠移植瘤生长的抑制作用。方法:采用人肝癌Hep G2裸鼠模型评估EVn-50在体治疗肝癌的有效性;免疫组化染色检测增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、CD31蛋白表达。结果:EVn-50显著抑制人肝癌Hep G2裸鼠移植瘤的生长,呈剂量依赖性;5,10,20 mg/kg的EVn-50对移植瘤的瘤重抑制率分别为55%,62%,69%。免疫组化染色结果显示,EVn-50(5,10,20 mg/kg)与生理盐水组比较,PCNA、VEGF、CD31的表达下调,亦呈剂量依赖性。结论:EVn-50具有抑制人肝癌HepG2裸鼠移植瘤生长作用,其作用机制可能与其下调PCNA、VEGF、CD31的表达有关。
OBJECTIVE: To observe the inhibitory effect of EVn-50 on the growth of human hepatoma Hep G2 xenografts in nude mice. Methods: The efficacy of EVn-50 in the treatment of hepatocellular carcinoma was evaluated by the Hep G2 model in nude mice. The proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry. ), CD31 protein expression. Results: EVn-50 significantly inhibited the growth of human hepatoma Hep G2 xenografts in a dose-dependent manner. The tumor weight inhibition rates of EVn-50 at 5, 10 and 20 mg / kg were 55% and 62% , 69%. Immunohistochemical staining showed that the expression of PCNA, VEGF and CD31 were down-regulated in a dose-dependent manner in EVn-50 (5, 10, and 20 mg / kg) CONCLUSION: EVn-50 can inhibit the growth of human hepatocarcinoma HepG2 xenografts in nude mice. The mechanism may be related to the downregulation of PCNA, VEGF and CD31 expression.